MABPLEX USA, INC provides the regulatory track record necessary to validate next-generation HER-2 ADCs and TROP-2 targets.
Public source
Publisher name
Public post
Recent data shows a consolidation toward well-validated targets like HER-2 and TROP-2. These targets appeared in 60% of recent abstracts at AACR 2026. They now serve as…
Company
MABPLEX USA, INC
MabPlex, your trusted CDMO partner for mAbs and ADC
- Industry
- Biotechnology Research
- Location
- San Diego, US
- Company size
- 2–10 employees
About MABPLEX USA, INC
MABPLEX USA, INC offers our partners contract services from DNA to finished drug product.
See moreLatest activity
Latest activity from MABPLEX USA, INC
12 signals
Products & Services
MABPLEX USA, INC scientists specialize in adapting conjugation chemistries for non-traditional payloads.
Products & Services
MABPLEX USA, INC provides specialized solubility protocols for non-cytotoxic payloads.
Products & Services
MABPLEX USA, INC provides comprehensive stability profiles for novel conjugates.
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
Guidant BioTherapeutics
Guidant BioTherapeutics built an ADC platform as a two-component, plug-and-play system targeting two tumor-targeting antibodies with an albumin-binding domain made in a single CHO-cell construct.
Products & Services
Kyinno Biotechnology, Inc.
Kyinno Biotechnology, Inc. supports antibody development with membrane-relocated overexpression (OE) cell models designed to present target proteins on the cell surface for functional binding analysis.
Products & Services
WuXi XDC
WuXi XDC developed the novel WuXiDARx conjugation platform providing a highly flexible target drug antibody ratio (DAR).
Products & Services
Abzena
Abzena runs head-to-head comparative studies across conjugation chemistry, release mechanism, and OAR early in development.
Products & Services
GBI Bio